Why Merck Stock Is Plummeting Today
Shares of Merck (MRK -9.66%) were trading lower on Tuesday. The company's stock had lost 10.1% as of 2 p.m.
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Healthcare costs are rising, with PwC projecting the highest commercial healthcare spending growth in 13 years, impacting consumers and insurance companies negatively. Healthcare stocks, including ...
Merck's soft guidance overshadows quarterly beat to send stock down 6%
Merck's stock tumbled 6% early Tuesday, after the drug company's softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.
Gardasil Worries Loom as Merck Reports Earnings
Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's overall clinical program data.
Unveiling Merck (MRK) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu...
Merck to stop lung condition drug study early due to strong efficacy data
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
FDA Grants Priority Review to Merck's Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraga...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts for Priority Review Merck's Application for WELIREG for Treatment of Advanced PPGL.
High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Merck's robust Phase 3 pipeline, strong financials, and sustainable ...
Exclusive: Kennedy played key role in vaccine case against Merck
Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los Angeles court next w...
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever
If you're looking at dividend stocks as a source of income, obviously quality matters. But timing can play a role in how much income these investments generate for you, too.
Merck Just Paid Investors: How Much Did They Receive?
Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable on Wednesday, Jan.
Merck's GARDASIL® Receives Expanded Approval for Males in China
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's GARDASIL® Receives Expanded Approval for Males in China.
Related Companies